Herein, given the success of GLP-1 analogs in phase II clinical trials (see section “Clinical trials show good protective effects in patients with AD or PD” for details), we will illustrate the manifold neuroprotective, cognition and motor-enhancing signaling pathways that are induced by the GLP-1R in detail and place them in the context with AD and PD. Here, GLP1R is linked to Alzheimer disease.